[Remote] Manager, Supply Chain Management at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Experience with material management of cGMP materials (Cell Banks, Drug Substance, and Drug Product)
Experience with logistics execution and oversight of DS and DP supply
Experience with Demand & Operations Planning (D&OP)
Experience with forecasting tools for clinical supply planning
Experience developing packaging and supply strategies
Experience with vendor management and RFPs
Experience with SOP development

Responsibilities

Maintain inventory oversight of applicable drug supply
Support logistics execution and oversight of DS and DP supply
Assist with assembly of bulk devices and allocation across studies
Develop and execute Demand & Operations Planning (D&OP)
Utilize forecasting tools to develop clinical supply forecasts
Develop packaging and supply strategies to meet clinical study needs
Clearly communicate expiry requirements
Represent Apogee with external providers
Manage oversight of packaging and labeling jobs
Develop requests for proposals for labeling, packaging, storage, and distribution
Review vendor invoices and provide input for accruals and budget
Coordinate US and international distribution and logistics for clinical studies
Drive development of Interactive Response Technology (IRT) user requirement specifications and acceptance testing

Skills

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free